| (Values in U.S. Thousands) | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 |
| Sales | 920 | 760 | 3,510 | 4,850 | 720 |
| Sales Growth | +21.05% | -78.35% | -27.63% | +573.61% | +9.09% |
| Net Income | -10,110 | -8,870 | -4,420 | -5,410 | -13,130 |
| Net Income Growth | -13.98% | -100.68% | +18.30% | +58.80% | +5.47% |
Scorpius Holdings Inc (SCPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Scorpius Holdings Inc. is an integrated contract development and manufacturing organization focused on advancing biologic and cell therapy programs to the clinic and beyond. Scorpius Holdings Inc., formerly known as NightHawk Biosciences, is based in DURHAM, N.C.
Fiscal Year End Date: 12/31